A systematic review of nineteen studies with 4375 patients, published Oct. 14, 2026, in the American Journal of Clinical Dermatology, found that tapering targeted eczema drugs often kept disease controlled better than…
Joint guidelines from the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation, published Oct. 20, 2026, make 37 recommendations, with strong support for four biologic drugs and for checking pain at…
A meta-analysis published Oct. 16, 2026, in BioDrugs found that 2.17% of people treated with biologics for psoriasis developed eczema-like reactions, most often with IL-17 inhibitors and least with IL-23 inhibitors.
A large records study published in October 2026 in Experimental Dermatology found that people with eczema treated with dupilumab didn't have a higher two-year risk of psoriasis than those on steroid creams,…
